MedTrace Logo

Study of High-dose, Intermittent Sunitinib in Patients With Solid Tumors.

NCT02058901 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 101

Last updated 2019-07-17

No results posted yet for this study

Summary

The primary objective of this study is:

* To determine the maximum tolerated dose (MTD) of sunitinib when administered once weekly or once every two weeks.
* To assess the safety and tolerability of sunitinib in a once weekly or once every two weeks dose schedule.

Conditions

Interventions

DRUG

Sunitinib

Sponsors & Collaborators

  • Amsterdam UMC, location VUmc

    lead OTHER

Principal Investigators

  • Henk MW Verheul, MD, PhD · Amsterdam UMC, location VUmc

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2019-06-30
Completion
2019-06-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02058901 on ClinicalTrials.gov